GLP1R and Insulin resistance: In this work, sitagliptin, a DPP-4 inhibitor that prevents GLP-1 degradation into GLP-1(9-36) and other metabolites, reduced hyperglycemia and insulin resistance, and increased GLP-1 levels in fasting and non-fasting states, as previously described [8, 31].